AGS‐16C3FAxitinibRenal cell carcinomaThe primary endpoint of this phase II study that evaluated the efficacy and safety of the investigational compound, AGSC3F, versus axitinib in previosuly treated patients with metastatic renal cell carcinoma (mRCC) was not met. The safety profile for each study...
In this study, we have found that human neoplastic MC lines (ROSAKITD816V and ROSAKITD816V-Gluc), which express high levels of CD203c, are highly and specifically sensitive to the antiproliferative effects of an ADC against CD203c (AGS-16C3F). In these cell lines, AGS-16C3F induced ...